Ice damages cellular life. Without freezing, the possibilities are life-changing.Learn More
CryoStasis’ revolutionary approach to preserving biological material traces its roots to the Canadian Arctic. Born of biochemist Olga Kukal’s fascination with the winter survival strategies of insects, our technology rejects a commonly held belief – that in order to preserve life, we must freeze it.
Our Novel Cold Chain Management Process
Proprietary storage solutions leverage unique cold shock inhibitors and membrane protectants to prevent cryoinjury to biological material.
Proprietary refrigeration devices, cold packs and shipping containers provide the flexibility needed to keep biological material viable for almost any storage or shipping scenario.
Proprietary, patent-pending pressurization technology depresses the freezing point of biological material, providing long-term enduring storage.
Until now, science has failed to keep organs viable post-harvest for more than a few hours. Our Extended Phase™️ technology enables safe kidney storage at -5°C without freezing for up to seven days, avoiding ischemic injury during the organ transplant process.Contact Us
Stem Cell Preservation
Freezing stem cells for research or therapy administration results in a high cell mortality rate, hindering patient care. Our Extended Phase™️ technology enables safe cell storage at -5°C without freezing for up to seven days, unlocking significant benefits to regenerative medicine.Contact Us
CryoStasis is currently collaborating with some of the world's foremost stem cell research and organ transplant centres.
This article describes the relevance of a QMS for leading medical device companies
CryoStasis technology is based on the belief that stored biological material is best preserved by reducing its metabolic rate and ischemic interval.
This hypothesis begs the question: How cold can something be stored in stable liquid state without freezing? The freezing point of a substance depends on its water content. An orange will not freeze until its temperature is below -2.1°C.
During the period from 2006 until 2018 the authors undertook a series to studies to determine the benefits of cold shock inhibitors, cryoprotectants, compounds that promote desiccation resistance, and increase membrane plasticity during cooling.
Jan brings decades of global growth and leadership experience to the CryoStasis team, including 15 years as President of Colonnade Investments. He’s guided venture-backed start-ups to successful M&As and held several advisory and board positions among a number of corporations and not-for-profits. His experience spans industries including agriculture, enterprise management, medical device technologies and more.
Chief Executive Officer
Keith has focused his career on disruptive products. Keith has been leading teams in various markets and industries for the last 25 years. Keith’s engineering background, MBA and leadership experience yields a powerful mix of business and technology skills. Keith has led teams in Aerospace, Healthcare, IT software & services. Keith has a proven record of successfully aligning company core competencies with customer problems.
Chief Science Officer
Tom is a physical chemist with an extensive academic and professional background. While doing a postdoctoral fellowship at Ohio State, Tom met his wife, Dr. Olga Kukal. Over the course of three decades, the two founded three biotechnical companies to actualize the transformative potential of Olga’s research. As CSO, Tom honours Olga’s memory by continuing to advance the research she began more than 40 years ago and that, together, they distilled into a life-changing technology.
Chief Medical Officer
Dr. Photis Loizides is a Plastic and Reconstructive Surgeon at Richmond Hospital and is the founder and operator of a successful Vancouver-based plastic surgery clinic. He is a Clinical Instructor of Surgery at the University of British Columbia. Fully accredited by the Royal College of Physicians and Surgeons, Photis has over a decade of experience performing reconstructive and cosmetic surgical procedures with extensive training in minimizing the effects of ischemic damage on tissues and organs.
Chief Financial Officer
Ross has more than 30 years’ senior financing, M&A, board of directors and operational experience supporting numerous early-stage, private and public companies, with a focus on high-tech. He is the current Managing Director of CFO4Results Inc., a consulting firm he acquired in 2010 and through which he’s advised dozens of companies ranging from biomedical to consumer products, patent licensing and software.
Chantal has over thirty years of combined technical and management experience in the biotech and telecommunications industries. In the past 17 years, she led teams in both small (<50) and medium (>500) size medical device organizations with focus on manufacturing, quality, and regulatory compliance. Chantal provided strategic and tactical leadership for manufacturing medical devices to achieve business critical objectives while meeting global regulatory and quality requirements and exceeding customer expectations. Chantal’s science and operations background, coupled with her passion for leading people, a strong combination with proven results.
We're on a mission to give life to research, healthcare, patients, and the world.Join Us